Drugmakers are reportedly preparing to raise U.S. prices on at least 350 branded medicines in 2026, including vaccines for COVID-19, RSV, and shingles, as well as major cancer therapies, despite pressure from the Trump administration to rein in costs.

Citing data provided exclusively by healthcare research firm 3 Axis Advisors, Reuters reported that the number of planned price increases is already higher than at the same point last year, when companies had flagged hikes on more than 250 drugs.

The median increase planned for 2026 is about 4%, roughly in line with increases seen for 2025.

Also Read: Judge Halts US Drug Discount Overhaul, Blocks 340B Rebate Plan

Reuters stated that the data reflect list price changes and do not account for rebates paid to pharmacy benefit managers or other behind-the-scenes discounts that can lower net prices for insurers.

Limited ...